SIOXClinical Trials•globenewswire•
Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204
Sentiment:Positive (70)
Summary
(SIOX) Strategic CRO to Support Path to Phase 2/3 Trials Following Recently Demonstrated Groundbreaking 97% Inhibition Rates for SIL204
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 4, 2025 by globenewswire